Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Celgene Corporation
Roche Pharma AG
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT01583426
First received: April 18, 2012
Last updated: October 11, 2016
Last verified: October 2016